Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €47.99 EUR
Change Today +0.57 / 1.20%
Volume 16.3K
DBV On Other Exchanges
EN Paris
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - €53.47
52 Week Low
05/2/14 - €14.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €280.0K
Compensation as of Fiscal Year 2013.

dbv technologies sa (DBV) Key Developments

DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children

DBV Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Viaskin® Peanut for children. Breakthrough Therapy Designation is intended to expedite the development and review of drugs/biological products for serious or life-threatening diseases or conditions, such as peanut allergy. Currently, DBV is actively preparing the launch of its Phase III trial of Viaskin Peanut in Children, suffering from peanut allergy, in close coordination with the US FDA. The FDA granted this Breakthrough Therapy Designation after DBV reported positive Phase IIb results with Viaskin Peanut. The Viaskin® Peanut Efficacy and Safety trial, or VIPES, is a Phase IIb study demonstrating that Viaskin Peanut 250 microgrammes improved the peanut allergy disease in children, as measured by a clinically significant endpoint. Available safety data from past and ongoing studies with Viaskin Peanut demonstrate an excellent safety profile in all age groups.

DBV Technologies S.A. Reports Audited Consolidated Earnings Results for the Full Year of 2014

DBV Technologies S.A. reported audited consolidated earnings results for the full year of 2014. For the period, total income was EUR 4.76 million against EUR 3.83 million a year ago. These revenues were primarily generated by Research Tax Credits, and to a lesser extent, by sales of Diallertest, as well as by subsidies received within the framework of research projects conducted by the company. Operating loss was EUR 24.64 million against EUR 19.95 million a year ago. Net loss was EUR 24.01 million or EUR 1.49 per share against EUR 19.31 million or EUR 1.42 per share a year ago. Net cash used in operating activities was EUR 20.56 million against EUR 13.25 million for the same period a year ago, primarily fuelled by increasing efforts engaged in R&D.

DBV Technologies Announces Board Changes

DBV Technologies announced the appointment of Daniel Soland to its Board of Directors. Mr. Soland will join as an independent board member, and will be part of DBV's audit committee. He most recently served as Senior Vice President and Chief Operating Officer of Viropharma, and currently serves on the Board of Tarsa Therapeutics. In addition to his role at Viropharma, Mr. Soland previously served as President of Chiron Vaccines. The company also announced that Dr. Didier Hoch has resigned from his position as Board member in agreement with Bpifrance.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €47.99 EUR +0.57

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr795.00 DKK -5.00
Allergy Therapeutics PLC 20.88 GBp +0.125
Merck & Co Inc $57.60 USD +0.09
Sanofi €95.86 EUR +0.51
Stallergenes SA €53.95 EUR +0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 151.4x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at